Mira Pharmaceuticals announces new results for Ketamir-2

Mira Pharmaceuticals announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir’s potential to provide therapeutic benefits without inducing schizophrenia-like behavior or hyper-locomotor activity. MIRA conducted the latest rigorous preclinical studies in collaboration with Biotrial to evaluate the effects of Ketamir-2 on spontaneous locomotor activity in mice. The studies are particularly significant for the treatment of mental health disorders and pain management, presenting a major advancement in the development of safer and more effective therapeutic options. Key findings from the study: Reduced Psychotic-like Symptoms: Unlike traditional ketamine, which resulted in marked and significant hyperlocomotion, Ketamir-2 did not produce incidences of inducing hyperlocomotion, schizophrenia-like behaviors in animal models, indicating a potentially safer profile for human patients, especially those with a predisposition to psychotic disorders. No Hyper-locomotor Activity: The study showed that while traditional ketamine induced hyperlocomotion, Ketamir-2, at same and higher doses compared with traditional ketamine, did not result in the hyper-locomotor activity, reducing the potential for misuse and enhancing patient safety. MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year.